Ascendis Pharma (ASND) Tops Q1 EPS by 9c

Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of EUR0.27, EUR0.09 better than the analyst estimate of EUR0.18. Revenue for the quarter came in at EUR246.6 million versus the consensus estimate of EUR269.95 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c